Summary: Genmab A/S' board of directors grants 505,250 warrants to members of
the board of directors, managers and employees of the company as well as the
company's subsidiaries.
Copenhagen, Denmark; October 8, 2008 - Genmab A/S (OMX: GEN) announced today
that on a board meeting the board decided to issue 505,250 warrants to members
of the board of directors, managers and employees of the company as well as the
company's subsidiaries
The exercise price for each warrant is DKK 272.00. Each warrant entitles the
owner to subscribe one share of nominally DKK 1. On the basis of an exercise
price of DKK 272.00 and by application of the Black-Scholes formula, the average
value of each warrant can be calculated as DKK 109.81 based on an interest rate
of 4.21% and the historical volatility of Genmab A/S shares calculated at
36.84%.
The warrants vest in blocks of 25% one, two, three and four years after the
grant date, and all warrants expire at the tenth anniversary of the grant date.
The new warrants were granted pursuant to the warrant plan adopted by the board
on August 3, 2004. Information concerning Genmab's warrant schemes can be found
on www.genmab.com under the heading ‘warrant scheme'.
About Genmab A/S
Genmab is a leading international biotechnology company focused on developing
fully human antibody therapeutics for unmet medical needs. Using cutting-edge
antibody technology, Genmab's world class discovery, development and
manufacturing teams have created and developed an extensive pipeline of products
for potential treatment of a variety of diseases including cancer and autoimmune
disorders. As Genmab advances towards a commercial future, we remain committed
to our primary goal of improving the lives of patients who are in urgent need of
new treatment options. For more information on Genmab's products and
technology, visit www.genmab.com.
This press release contains forward looking statements. The words “believe”,
“expect”, “anticipate”, “intend” and “plan” and similar expressions identify
forward looking statements. Actual results or performance may differ materially
from any future results or performance expressed or implied by such statements.
The important factors that could cause our actual results or performance to
differ materially include, among others, risks associated with product discovery
and development, uncertainties related to the outcome and conduct of clinical
trials including unforeseen safety issues, uncertainties related to product
manufacturing, the lack of market acceptance of our products, our inability to
manage growth, the competitive environment in relation to our business area and
markets, our inability to attract and retain suitably qualified personnel, the
unenforceability or lack of protection of our patents and proprietary rights,
our relationships with affiliated entities, changes and developments in
technology which may render our products obsolete, and other factors. For a
further discussion of these risks, please refer to the section “Risk Management”
in Genmab's Annual Report, which is available on www.genmab.com. Genmab does
not undertake any obligation to update or revise forward looking statements in
this press release nor to confirm such statements in relation to actual results,
unless required by law.
Genmab(R); the Y-shaped Genmab logo(R); HuMax(R); HuMax-CD4(R); HuMax-CD20(R);
HuMax-EGFr(TM); HuMax-IL8(TM); HuMax-TAC(TM); HuMax-HepC(TM); HuMax-CD38(TM);
HuMax-CD32b(TM) and UniBody(R) are all trademarks of Genmab A/S.
Contact: Helle Husted, Sr. Director, Investor Relations, T: +45 33 44 77 30, M:
+45 25 27 47 13, E: hth@genmab.com
Stock Exchange Release no. 47/2008
###
